Literature DB >> 18410503

Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.

Arianna Bellucci1, Ginetta Collo, Ilenia Sarnico, Leontino Battistin, Cristina Missale, Pierfranco Spano.   

Abstract

Progressive degeneration and intraneuronal Lewy bodies made of filamentous alpha-synuclein (alpha-syn) in dopaminergic cells of the nigrostriatal system are characteristics of Parkinson's disease (PD). Glucose uptake is reduced in some of the brain regions affected by PD neurodegenerative changes. Defects in mitochondrial activity in the substantia nigra have been observed in the brain of patients affected by PD and substantia nigra lesions can induce the onset of a secondary parkinsonism. Thus, energy starvation and consequently metabolic impairment to dopaminergic neurons may be related to the onset of PD. On this line, we evaluated the effect of nutrient starvation, reproduced 'in vitro' by glucose deprivation (GD), in primary mesecephalic neuronal cultures and dopaminergic-differentiated SH-SY5Y cells, to evaluate if decreased glucose support to dopaminergic cells can lead to mitochondrial damage, neurodegeneration and alpha-syn misfolding. Furthermore, we investigated the effect of dopamine (DA) treatment in the presence of a DA-uptake inhibitor or of the D(2)/D(3) receptor (D(2)R/D(3)R) agonist quinpirole on GD-treated cells, to evaluate the efficacy of these therapeutic compounds. We found that GD induced the formation of fibrillary aggregated alpha-syn inclusions containing the DA transporter in dopaminergic cells. These alterations were accompanied by dopaminergic cell death and were exacerbated by DA overload. Conversely, the block of DA uptake and D(2)R/D(3)R agonist treatment exerted neuroprotective effects. These data indicate that glucose starvation is likely involved in the induction of PD-related pathological changes in dopaminergic neurons. These changes may be counteracted by the block of DA uptake and by dopaminergic agonist treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18410503     DOI: 10.1111/j.1471-4159.2008.05406.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  31 in total

1.  SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease.

Authors:  Pablo Garcia-Reitböck; Oleg Anichtchik; Arianna Bellucci; Mariangela Iovino; Chiara Ballini; Elena Fineberg; Bernardino Ghetti; Laura Della Corte; PierFranco Spano; George K Tofaris; Michel Goedert; Maria Grazia Spillantini
Journal:  Brain       Date:  2010-06-09       Impact factor: 13.501

Review 2.  Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.

Authors:  Annadurai Anandhan; Maria S Jacome; Shulei Lei; Pablo Hernandez-Franco; Aglaia Pappa; Mihalis I Panayiotidis; Robert Powers; Rodrigo Franco
Journal:  Brain Res Bull       Date:  2017-03-21       Impact factor: 4.077

3.  The plasma membrane redox enzyme NQO1 sustains cellular energetics and protects human neuroblastoma cells against metabolic and proteotoxic stress.

Authors:  Dong-Hoon Hyun; Jiyeong Kim; Chanil Moon; Chang-Jin Lim; Rafael de Cabo; Mark P Mattson
Journal:  Age (Dordr)       Date:  2011-04-13

4.  Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons.

Authors:  Federica Bono; Paola Savoia; Adele Guglielmi; Massimo Gennarelli; Giovanna Piovani; Sandra Sigala; Damiana Leo; Stefano Espinoza; Raul R Gainetdinov; Paola Devoto; PierFranco Spano; Cristina Missale; Chiara Fiorentini
Journal:  Mol Neurobiol       Date:  2017-01-14       Impact factor: 5.590

Review 5.  α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease.

Authors:  Zachary A Sorrentino; Benoit I Giasson; Paramita Chakrabarty
Journal:  Acta Neuropathol       Date:  2019-02-23       Impact factor: 17.088

6.  Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability.

Authors:  Li Rebekah Feng; Howard J Federoff; Stefano Vicini; Kathleen A Maguire-Zeiss
Journal:  Eur J Neurosci       Date:  2010-06-14       Impact factor: 3.386

Review 7.  Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas.

Authors:  Estela Area-Gomez; Cristina Guardia-Laguarta; Eric A Schon; Serge Przedborski
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

8.  Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.

Authors:  Balaram Ghosh; Tamara Antonio; Juan Zhen; Prashant Kharkar; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

9.  White matter hypoperfusion and damage in dementia: post-mortem assessment.

Authors:  Seth Love; J Scott Miners
Journal:  Brain Pathol       Date:  2015-01       Impact factor: 6.508

Review 10.  Reappraisal of metabolic dysfunction in neurodegeneration: Focus on mitochondrial function and calcium signaling.

Authors:  Pooja Jadiya; Joanne F Garbincius; John W Elrod
Journal:  Acta Neuropathol Commun       Date:  2021-07-07       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.